Protocol Ledger

NCT03773302 · Phase III · TERMINATED

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Interventional Phase III clinical trial protocol NCT03773302 sponsored by QED Therapeutics, a BridgeBio company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-27 Enrollment: 48 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03773302
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03773302
Protocol FieldVerified Registry Value
NCT IdentifierNCT03773302
Consolidated Lead SponsorQED Therapeutics, a BridgeBio company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment48 participants (ACTUAL)
Registered Start Date2019-12-27
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI